PMID- 32162757
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 1540-8167 (Electronic)
IS  - 1045-3873 (Linking)
VI  - 31
IP  - 5
DP  - 2020 May
TI  - Performance of a novel active fixation quadripolar left ventricular lead for 
      cardiac resynchronization therapy: Attain Stability Quad Clinical Study results.
PG  - 1147-1154
LID - 10.1111/jce.14439 [doi]
AB  - INTRODUCTION: The Medtronic Attain Stability Quad lead is a quadripolar left 
      ventricular (LV) lead with an active fixation helix assembly designed to fixate 
      the lead within the coronary sinus and pace nonapical regions of the LV. The 
      primary objective of this study was to determine the safety and effectiveness of 
      this novel active fixation quadripolar LV lead. METHODS: Patients with standard 
      indications for cardiac resynchronization therapy (CRT) were enrolled. All 
      patients were followed at 3 and 6 months post-implant and every 6 months 
      thereafter until study closure. Pacing capture thresholds (PCTs) were measured at 
      implant and each follow-up and adverse events (AEs) were recorded upon 
      occurrence. RESULTS: Of the 440 patients who underwent implant procedures, 
      placement of the Attain Stability Quad lead was successful in 426 (96.8%). LV 
      lead-related complications occurred in 10 patients (2.3%), including LV lead 
      dislodgement in three patients (0.7%). The percentage of patients with at least 
      one LV pacing vector with a PCT </=2.5 V at a 6-month follow-up was 96.3%. The LV 
      lead was successfully fixated to the prespecified pacing location in 97.4% of 
      cases. CONCLUSIONS: This large, multinational study of the Attain Stability Quad 
      lead demonstrated a high rate of implant success with a low complication rate. 
      The active fixation mechanism allowed precise placement of the pacing electrodes 
      at the desired target region with good PCTs and a very low dislodgement rate.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Jackson, Kevin P
AU  - Jackson KP
AUID- ORCID: 0000-0002-2948-1333
AD  - Division of Cardiology, Duke University Medical Center, Durham, North Carolina.
FAU - Faerestrand, Svein
AU  - Faerestrand S
AD  - Department of Clinical Science, University of Bergen and Haukeland University 
      Hospital, Bergen, Norway.
FAU - Philippon, Francois
AU  - Philippon F
AD  - Department of Medicine, Institut Universitaire De Cardiologie Et De Pneumologie 
      De Quebec, Quebec, Canada.
FAU - Yee, Raymond
AU  - Yee R
AD  - Division of Cardiology, University Hospital, London, Ontario, Canada.
FAU - Kong, Melissa H
AU  - Kong MH
AD  - Silicon Valley Hospital, Redwood City, California.
FAU - Kloppe, Axel
AU  - Kloppe A
AD  - Medizinische Klinik II, BG Universitatsklinikum Bergmannsheil, Bochum, Germany.
FAU - Bongiorni, Maria Grazia
AU  - Bongiorni MG
AD  - Cardiology Department, University Hospital of Pisa, Pisa, Italy.
FAU - Lee, Scott F
AU  - Lee SF
AD  - Baptist Heart Specialists, Ponte Vedra Beach, Florida.
FAU - Canby, Robert C
AU  - Canby RC
AD  - Texas Cardiac Arrhythmia Research, Austin, Texas.
FAU - Pouliot, Erika
AU  - Pouliot E
AD  - Medtronic Inc., Mounds View, Minnesota.
FAU - van Ginneken, Mireille M E
AU  - van Ginneken MME
AD  - Medtronic Bakken Research Center, Maastricht, The Netherlands.
FAU - Crossley, George H
AU  - Crossley GH
AUID- ORCID: 0000-0003-0096-8401
AD  - Division of Cardiology, Vanderbilt University Heart and Vascular Institute, 
      Nashville, Tennessee.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200318
PL  - United States
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cardiac Resynchronization Therapy/adverse effects
MH  - *Cardiac Resynchronization Therapy Devices
MH  - Equipment Design
MH  - Female
MH  - Heart Failure/diagnosis/physiopathology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
OTO - NOTNLM
OT  - LV lead
OT  - active fixation
OT  - cardiac resynchronization therapy
OT  - lead dislodgement
OT  - quadripolar lead
EDAT- 2020/03/13 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/03/13 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/01 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2020/03/13 06:00 [entrez]
AID - 10.1111/jce.14439 [doi]
PST - ppublish
SO  - J Cardiovasc Electrophysiol. 2020 May;31(5):1147-1154. doi: 10.1111/jce.14439. 
      Epub 2020 Mar 18.